Phase II, proof-of-concept, sham-controlled, double-masked trial evaluating the safety, tolerability, and efficacy of KVD001 in Subjects with Diabetic Macular Edema

Trial Profile

Phase II, proof-of-concept, sham-controlled, double-masked trial evaluating the safety, tolerability, and efficacy of KVD001 in Subjects with Diabetic Macular Edema

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs KVD 001 (Primary)
  • Indications Diabetic macular oedema
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Jan 2018 According to a KalVista Pharmaceuticals media release, top-line results are expected in the second half of 2019.
    • 05 Jan 2018 Status changed from planning to recruiting, as reported in a KalVista Pharmaceuticals media release.
    • 22 Nov 2016 According to a KalVista Pharmaceuticals media release, this study is expected to start in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top